ClinicalTrials.govpublic full text
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
nsclc, late or metastatic non-squamous non-small cells, egfr mutations patients, cell lung cancer., interventional, phase2, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 887412
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.